Testing a treatment plan for children and young adults with NGGCT brain tumors
Original title: A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the treatment has been tested in people before but is still being studied.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests how to match chemotherapy and radiation to how well a tumor responds to early treatment.
Who this trial is for. This trial is for children and young adults with a brain tumor called NGGCT that has not spread to other parts of the brain or body. Everyone starts with chemotherapy, and the answer to that first round decides what comes next: radiation to the spine and part of the brain, or higher dose chemotherapy with a stem cell transplant before radiation to the whole brain and spine.
Where it stands. This trial has not reported results. It is measuring how well tumors respond to the first round of chemotherapy, and using that to pick the next treatment. The team hopes this lowers radiation side effects for some patients and gives others a better matched treatment. Whether it works is not known yet.
What this means, and what it doesn't
What it could mean: If you or your child has this type of tumor, this trial may be worth asking your care team about. They can tell you if it fits your situation. They can also explain the treatments being tested and what taking part would involve.
What it doesn't mean: This does not mean the treatment plan is proven. A trial is a test, not care your own doctor can give you. Joining a trial is not a guarantee that it will help. And it is not a promise of a cure.
Source: ClinicalTrials.gov, August 25, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.